The therapeutic potential of the cannabinoids in neuroprotection.

Abstract:

:After thousands of years of interest the last few decades have seen a huge increase in our knowledge of the cannabinoids and their mode of action. Their potential as medical therapeutics has long been known. However, very real concerns over their safety and efficacy have lead to caution and suspicion when applying the legislature of modern medicine to these compounds. The ability of this diverse family of compounds to modulate neurotransmission and act as anti-inflammatory and antioxidative agents has prompted researchers to investigate their potential as neuroprotective agents. Indeed, various cannabinoids rescue dying neurones in experimental forms of acute neuronal injury, such as cerebral ischaemia and traumatic brain injury. Cannabinoids also provide symptomatic relief in experimental models of chronic neurodegenerative diseases, such as multiple sclerosis and Huntington's disease. This preclinical evidence has provided the impetus for the launch of a number of clinical trials in various conditions of neurodegeneration and neuronal injury using compounds derived from the cannabis plant. Our understanding of cannabinoid neurobiology, however, must improve if we are to effectively exploit this system and take advantage of the numerous characteristics that make this group of compounds potential neuroprotective agents.

authors

Grundy RI

doi

10.1517/13543784.11.10.1365

subject

Has Abstract

pub_date

2002-10-01 00:00:00

pages

1365-74

issue

10

eissn

1354-3784

issn

1744-7658

journal_volume

11

pub_type

杂志文章,评审
  • Investigational drugs for coagulation disorders.

    abstract:INTRODUCTION:The current standard treatment in persons with hemophilia (PWH) is prophylaxis, given intravenously twice or thrice weekly, which is associated with a non negligible burden on patients' quality of life. Therefore the main attempts aiming to improve the management of PWH are targeted towards the development...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2013.798302

    authors: Mannucci PM,Mancuso ME

    更新日期:2013-08-01 00:00:00

  • The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.

    abstract:INTRODUCTION:Although significant advances have been made in the treatment of advanced renal cell carcinoma (RCC), patients still develop resistance to standard therapies and require the administration of subsequent lines of treatment. New therapeutic approaches are thus imperative to improve the prognosis for patients...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2018.1427731

    authors: Bilen MA,Carlisle JW,Sonpavde G

    更新日期:2018-02-01 00:00:00

  • Discontinued drugs in 2006: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs.

    abstract::This perspective is the second in a series discussing drugs dropped from development in 2006, with a focus on pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs. A survey of discontinued drugs from 2006 is provided, based on data from the Pharmaprojects database, along with an analysis of biology,...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.9.1327

    authors: Ozdemir C,Akdis CA

    更新日期:2007-09-01 00:00:00

  • How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.

    abstract:INTRODUCTION:Relapsed/refractory multiple myeloma (rrMM) remains a difficult condition to treat despite the availability of new drugs. This review aims to provide evidence to guide physicians in the choice of salvage therapy in certain subgroups of patients. AREAS COVERED:The review attempts to present evidence-based ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2011.575060

    authors: Offidani M,Corvatta L,Morabito F,Gentile M,Musto P,Leoni P,Palumbo A

    更新日期:2011-06-01 00:00:00

  • Lebrikizumab for the treatment of asthma.

    abstract:INTRODUCTION:In asthma, most commonly, 'conventional' anti-inflammatory medications represented by inhaled corticosteroids and leukotriene inhibitors are effective. In some patients however additional inhibition of the airways inflammation is necessary. Such compounds might be molecules inhibiting specifically certain ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2016.1227319

    authors: Antoniu SA

    更新日期:2016-10-01 00:00:00

  • PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.

    abstract:INTRODUCTION:Gut-specific homing is mainly mediated by the expression of MAdCAM-1 on endothelial cells. An increase in MAdCAM-1 expression has been shown in patients with inflammatory bowel disease (IBD). Areas covered: PF-00547659 is a fully human monoclonal antibody (mAb) toward MAdCAM-1 on endothelial cells, blockin...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2018.1494722

    authors: Allocca M,Gilardi D,Fiorino G,Furfaro F,Argollo M,Peyrin-Biroulet L,Danese S

    更新日期:2018-07-01 00:00:00

  • Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development.

    abstract::This review highlights some important advances that have taken place in cannabinoid research over the last four years. It focuses on novel ligands that are of interest either as experimental tools or as lead compounds for therapeutic agents and possible clinical applications for some of these ligands. The molecular ta...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.7.1553

    authors: Pertwee RG

    更新日期:2000-07-01 00:00:00

  • Aripiprazole acts as a selective dopamine D2 receptor partial agonist.

    abstract::Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacological profile. It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.6.771

    authors: Wood M,Reavill C

    更新日期:2007-06-01 00:00:00

  • Dehydroaltenusin is a specific inhibitor of mammalian DNA polymerase α.

    abstract:INTRODUCTION:We carried out a screen for small molecule selective inhibitors of eukaryotic DNA polymerases (pols). Dehydroaltenusin, isolated from a fungus (Alternaria tenuis), was found to be a specific inhibitor of pol α. AREAS COVERED:We succeeded in chemically synthesizing dehydroaltenusin along with five analogs....

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2011.619977

    authors: Mizushina Y,Maeda N,Kuriyama I,Yoshida H

    更新日期:2011-11-01 00:00:00

  • Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes.

    abstract::Bromocriptine, a potent dopamine D(2) receptor agonist, has been shown to reduce insulin resistance, glucose intolerance and hyperlipidaemia in both numerous animal studies and in Phase II studies. Bromocriptine has been used worldwide for over 20 years to treat Parkinson's disease, macroprolactinoma and other disorde...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.8.10.1683

    authors: Cincotta AH,Meier AH,Cincotta M Jr

    更新日期:1999-10-01 00:00:00

  • Investigational vasopressin receptor modulators in the pipeline.

    abstract::The vasopressin system is complex and interacts with the central nervous, cardiovascular, renal, and hematological systems. Vasopressin plays an important role in the control of blood osmolarity and vascular tone, but is also involved in many other physiological events, which are mediated mainly via three types of vas...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780903066764

    authors: Favory R,Salgado DR,Vincent JL

    更新日期:2009-08-01 00:00:00

  • Therapeutic use of the high-density lipoprotein protein and peptides.

    abstract::High-density lipoprotein (HDL) therapy is a novel and emerging area of therapeutic development in the cardiovascular field. It attempts to supplement and improve the vascular benefit exerted by other agents that are active on lipid metabolism, for example, hypolipidaemic drugs. Furthermore, it takes advantage of the n...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.3.227

    authors: Marchesi M,Sirtori CR

    更新日期:2006-03-01 00:00:00

  • Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective.

    abstract:IMPORTANCE OF THE FIELD:Curcumin has been investigated in preclinical and translational stroke models because of its pleiotropic 'neuroprotective' activities. Since curcumin has poor blood-brain barrier (BBB) penetration following acute administration, creative medicinal chemistry has been used to modify the parent cur...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2011.542410

    authors: Lapchak PA

    更新日期:2011-01-01 00:00:00

  • Urokinase receptor antagonists: novel agents for the treatment of cancer.

    abstract::The interaction between the urokinase receptor (uPAR) and its ligand urokinase (uPA) mediates phenomena such as tissue remodelling, chemotaxis, tumour invasion, dissemination, proliferation, and angiogenesis. The broad-spectrum of biological processes that the uPA/uPAR interaction plays a role in has led researchers t...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.3.391

    authors: Weidle UH,König B

    更新日期:1998-03-01 00:00:00

  • Lenalidomide for the treatment of B-cell lymphoma.

    abstract:INTRODUCTION:Although the combination of an anti-CD20 monoclonal antibody and chemotherapy has widely improved survival of patients with B-cell lymphoma, the disease still relapses. A better understanding of the biology of lymphomas has highlighted the role of the cell of origin in response to treatment and outcome. Le...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2016.1208170

    authors: Garciaz S,Coso D,Schiano de Colella JM,Bouabdallah R

    更新日期:2016-09-01 00:00:00

  • Recombinant toxins in haematologic malignancies and solid tumours.

    abstract::Recombinant toxins constitute a new modality for the treatment of cancer, since they target cells displaying specific surface-receptors or antigens. They are fusion proteins, which contain toxin and ligand regions, and are produced in Escherichia coli. The ligand may be a growth factor or a fragment of an antibody, an...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.9.1405

    authors: Kreitman RJ

    更新日期:1998-09-01 00:00:00

  • Drugs in preclinical to phase II clinical development for the treatment of erectile dysfunction.

    abstract:INTRODUCTION:Erectile function is an important aspect in the quality of life of many men. For men with erectile dysfunction (ED), a spectrum of treatment options exists. Novel therapies for ED are currently being developed in order to delay surgical placement of a penile prosthesis - the final step in the management of...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1324570

    authors: Smith-Harrison L,Starke NR,Smith RP,Kovac JR

    更新日期:2017-06-01 00:00:00

  • Potential use of exenatide for the treatment of obesity.

    abstract:INTRODUCTION:Obesity is a major health threat in the Western world because of its high incidence and prevalence, and its association with metabolic and cardiovascular disease as well as cancer. The reduction of food intake in obese patients can be achieved only transiently (generally for no longer than 6 months), in th...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2011.630660

    authors: Folli F,Guardado Mendoza R

    更新日期:2011-12-01 00:00:00

  • Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers.

    abstract::Introduction: Neuropathic pain is a chronic condition that significantly affects the quality of life of millions of people globally. Most of the pharmacologic treatments currently in use demonstrate modest efficacy and over half of all patients do not respond to medical management. Hence, there is a need for new, effi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2020.1728254

    authors: Kushnarev M,Pirvulescu IP,Candido KD,Knezevic NN

    更新日期:2020-03-01 00:00:00

  • Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.

    abstract::This paper reviews the clinical pharmacology, efficacy and safety of the novel antipsychotic drug aripiprazole. All published citations regarding aripiprazole were reviewed using a Medline((R)) search (completed for citations through mid-year, 2002). In addition, abstracts from recent scientific meetings presenting da...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.4.655

    authors: Keck PE Jr,McElroy SL

    更新日期:2003-04-01 00:00:00

  • Therapeutic targets and early stage clinical trials for pulmonary fibrosis.

    abstract:INTRODUCTION:Idiopathic pulmonary fibrosis (IPF) is an age-associated, progressive, and irreversible fatal interstitial lung disease. Although many drugs have failed in clinical trials, these failures improved the understanding of the pathogenesis of IPF. Currently, there are two drugs approved for IPF that slow the pr...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2019.1554054

    authors: Sato S,Yanagihara T,Kolb MRJ

    更新日期:2019-01-01 00:00:00

  • The therapeutic effects of vitamin D3 and its analogues in psoriasis.

    abstract::Psoriasis is a common skin disease which is characterised by the proliferation and abnormal differentiation of keratinocytes, coupled with complex immune disturbances. The beneficial effects of vitamin D derivatives in this disease are due to their capacity to inhibit proliferation, their ability to induce normal diff...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.1.77

    authors: Guilhou JJ

    更新日期:1998-01-01 00:00:00

  • Dronedarone: an amiodarone analogue.

    abstract::Of the antiarrhythmic drugs in current use, amiodarone is one of the most effective and is associated with a comparatively low risk of drug-induced pro-arrhythmia, probably due to its multiple pharmacological actions on cardiac ion channels and receptors. However, amiodarone is associated with significant extra-cardia...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.4.415

    authors: Doggrell SA,Hancox JC

    更新日期:2004-04-01 00:00:00

  • Alpha-lipoic acid, an anti-obesity agent?

    abstract::Obesity shortens life expectancy and is a risk factor for hypertension and Type 2 diabetes. When added to the standard chow of Sprague-Dawley or Otsuka Long-Evans Tokushima Fatty rats, alpha-lipoic acid (0.5% weight/weight) reduced body weight and food intake. Alpha-lipoic acid also increased whole-body energy expendi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.12.1641

    authors: Doggrell SA

    更新日期:2004-12-01 00:00:00

  • Antisense approach for the treatment of cytomegalovirus infection.

    abstract::Human cytomegalovirus (HCMV) is the most common viral opportunistic infection in patients suffering with acquired immunodeficiency virus (AIDS). HCMV is a systemic infection that may infect several sites in the body, including the retina, gastrointestinal tract, lungs, liver, and central nervous system. Retinitis is t...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.9.1157

    authors: Temsamani J,Pari GS,Guinot P

    更新日期:1997-09-01 00:00:00

  • Novel approaches for the prevention of restenosis.

    abstract::Restenosis, the re-narrowing of the lumen of the coronary artery, in the months following a successful percutaneous balloon angioplasty or stenting, remains the main limitation to percutaneous coronary revascularisation. Serial intravascular ultrasound studies have shown that restenosis after conventional balloon angi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.11.2555

    authors: Gruberg L,Waksman R,Satler LF,Pichard AD,Kent KM

    更新日期:2000-11-01 00:00:00

  • Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004.

    abstract::Recent advances in the treatment and management of haematological malignancies are due in large part to an improved understanding of the basic biology that drives tumour cell growth and survival. This improved understanding has led to the clinical study and approval of a number of different targeted agents across a nu...

    journal_title:Expert opinion on investigational drugs

    pub_type:

    doi:10.1517/13543784.14.9.1161

    authors: Haas M,Lonial S

    更新日期:2005-09-01 00:00:00

  • New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

    abstract:IMPORTANCE OF THE FIELD:Contrasting with the broad activation of the PI3K/AKT/mammalian target of rapamycin (mTOR) survival pathway in most cancer, activity of rapalogues appears to be restricted to a few tumor types. AREAS COVERED IN THIS REVIEW:The analysis of molecular activity of the PI3K/AKT/mTOR pathway and resi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.499121

    authors: Albert S,Serova M,Dreyer C,Sablin MP,Faivre S,Raymond E

    更新日期:2010-08-01 00:00:00

  • Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice.

    abstract::Proliferative diabetic retinopathy (PDR) demands both more effective and less expensive biologically based treatments. Our understanding of the pathophysiology of the disease is increasing as new biochemical pathways are identified. Most reports emphasize proangiogenic stimuli, with the natural inhibitory elements rec...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.8.1209

    authors: Hernández C,Simó R

    更新日期:2007-08-01 00:00:00

  • Dawn of Aurora kinase inhibitors as anticancer drugs.

    abstract::With the current standard chemotherapy regimens only approximately 25% of acute myelogenous leukaemia (AML) patients survive > 5 years. Aurora kinases are overexpressed in many human cancers. VX-680 inhibited Aurora-A, -B, -C and the FMS-like tyrosine kinase-3 with apparent inhibitory constants of 0.6, 18, 4.6 and 30 ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.9.1199

    authors: Doggrell SA

    更新日期:2004-09-01 00:00:00